David Steensma

Hematologist-Oncologist at Dana-Farber Cancer Institute
Summary
Dr. David Steensma is a highly accomplished individual known for his expertise in various myeloid neoplasms such as myelodysplastic syndromes, acute myeloid leukemia, and chronic myeloid leukemia.
He is a specialist in bone marrow failure syndromes, sideroblastic anemias, prognostic modeling, phenotype-genotype correlations, and clinical trial development.
Dr. Steensma holds a diverse educational background, including studies in Molecular Haematology at the University of Oxford, Internal Medicine, Hematology, and Oncology at the Mayo Clinic Graduate School of Biomedical Sciences, and Medicine at The University of Chicago Pritzker School of Medicine.
Furthermore, he pursued a B.S. in Physics and Astronomy at Calvin University.
Currently, Dr. Steensma serves as the Edward P. Evans Chair in MDS Research at the Dana-Farber Cancer Institute, showcasing his leadership and commitment to advancing the field of hematology.
His previous roles include being an Associate Professor of Medicine at Harvard Medical School, as well as an Attending Physician in the Hematological Malignancies Service at Brigham and Women's Hospital.
Dr. Steensma also contributed his expertise as a former Voting Member of the Oncology Drug Advisory Committee (ODAC) at the FDA, emphasizing his involvement in regulatory affairs within the medical community.
With a rich and varied professional history, including positions at renowned institutions like the Dana-Farber Cancer Institute, Mayo Clinic, and University of Oxford, Dr. Steensma has accumulated a wealth of experience in hematology and oncology.
His early career included roles as an Astronomical Observatory Assistant and Physics Laboratory Assistant at Calvin College, reflecting his multidisciplinary interests and versatile skill set.
Throughout his career, Dr. Steensma has demonstrated a dedication to research, clinical practice, and education, making significant contributions to the field of hematology and advancing patient care.
His work spans from fundamental research on myeloid neoplasms to practical applications in clinical trial development, highlighting his comprehensive approach to addressing complex medical challenges.